Incretin-based drugs and intestinal obstruction: A pharmacovigilance study

What is already known about this subject• Incretin-based drugs induce a reduction in intestinal motility• The risk of intestinal obstruction associated with incretin-based drugs is suspected from post-marketing data What this study adds• We identified a pharmacovigilance signal that suggests a risk of potentially serious intestinal obstruction associated with incretin-based drugs, as a class and with a greater signal for DPP4-i.